These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 29451342

  • 1. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [Abstract] [Full Text] [Related]

  • 2. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M, Boratyńska M, Kościelska-Kasprzak K, Kamińska D, Bartoszek D, Zabińska M, Myszka M, Zmonarski S, Protasiewicz M, Nowakowska B, Hałoń A, Chudoba P, Klinger M.
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [Abstract] [Full Text] [Related]

  • 3. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A, Süsal C, Schröder C, Höcker B, Rieger S, Waldherr R, Westhoff JH, Sander A, Dragun D, Tönshoff B.
    Nephrol Dial Transplant; 2018 Jun 01; 33(6):1065-1072. PubMed ID: 29444269
    [Abstract] [Full Text] [Related]

  • 4. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M, Foucher Y, Dufay A, Duong Van Huyen JP, Renaudin K, Moreau A, Philippe A, Hegner B, Dechend R, Heidecke H, Brouard S, Cesbron A, Castagnet S, Devys A, Soulillou JP, Dragun D.
    Am J Transplant; 2013 Oct 01; 13(10):2567-76. PubMed ID: 23919486
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
    Deltombe C, Gillaizeau F, Anglicheau D, Morelon E, Trébern-Launay K, Le Borgne F, Rimbert M, Guérif P, Malard-Castagnet S, Foucher Y, Giral M.
    Transpl Int; 2017 Nov 01; 30(11):1150-1160. PubMed ID: 28686316
    [Abstract] [Full Text] [Related]

  • 7. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H, Kim JI, Moon IS, Chung BH, Yang CW, Kim Y, Han K, Oh EJ.
    Ann Lab Med; 2015 May 01; 35(3):314-20. PubMed ID: 25932439
    [Abstract] [Full Text] [Related]

  • 8. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E, Arreola-Guerra JM, Hernández-Méndez EA, Salcedo I, Castelán N, Uribe-Uribe NO, Vilatobá M, Contreras-Saldívar AG, Sánchez-Cedillo AI, Ramírez JB, de Rungs D, Granados J, Morales-Buenrostro LE, Alberú J.
    Nephrol Dial Transplant; 2016 Oct 01; 31(10):1738-45. PubMed ID: 27220757
    [Abstract] [Full Text] [Related]

  • 9. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
    Reinsmoen NL, Mirocha J, Ensor CR, Marrari M, Chaux G, Levine DJ, Zhang X, Zeevi A.
    Transplantation; 2017 Jun 01; 101(6):1215-1221. PubMed ID: 27973391
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients.
    Sorohan BM, Ismail G, Berechet A, Obrișcă B, Constantinescu I, Mărunțelu I, Tacu D, Baston C, Sinescu I.
    Transpl Immunol; 2021 Jun 01; 66():101389. PubMed ID: 33838295
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.
    Taniguchi M, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, Catrou PG, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI.
    Am J Transplant; 2013 Oct 01; 13(10):2577-89. PubMed ID: 23941128
    [Abstract] [Full Text] [Related]

  • 14. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis.
    Kang ZY, Liu C, Liu W, Li DH.
    Nephrol Dial Transplant; 2022 May 25; 37(6):1171-1180. PubMed ID: 34865146
    [Abstract] [Full Text] [Related]

  • 15. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.
    Lee J, Huh KH, Park Y, Park BG, Yang J, Jeong JC, Lee J, Park JB, Cho JH, Lee S, Ro H, Han SY, Kim MS, Kim YS, Kim SJ, Kim CD, Chung W, Park SB, Ahn C, KNOW-KT Study Group.
    Nephrol Dial Transplant; 2017 Jul 01; 32(7):1244-1250. PubMed ID: 26546592
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D, Lee J, Schwartz JE, Friedlander R, Aull M, Muthukumar T, Campbell S, Epstein D, Seshan SV, Kapur S, Sharma VK, Suthanthiran M, Dadhania D.
    Transplantation; 2015 Jun 01; 99(6):1156-64. PubMed ID: 25629531
    [Abstract] [Full Text] [Related]

  • 17. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.
    Transpl Int; 2017 Apr 01; 30(4):347-359. PubMed ID: 27717025
    [Abstract] [Full Text] [Related]

  • 18. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
    Reinsmoen NL, Lai CH, Mirocha J, Cao K, Ong G, Naim M, Wang Q, Haas M, Rafiei M, Czer L, Patel J, Kobashigawa J.
    Transplantation; 2014 Mar 15; 97(5):595-601. PubMed ID: 24162250
    [Abstract] [Full Text] [Related]

  • 19. Impact on mid-term kidney graft outcomes of pretransplant anti-HLA antibodies detected by solid-phase assays: Do donor-specific antibodies tell the whole story?
    Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.
    Hum Immunol; 2017 Sep 15; 78(9):526-533. PubMed ID: 28732720
    [Abstract] [Full Text] [Related]

  • 20. Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years.
    Aziz F, Jung-Hynes B, Parajuli S, Redfield RR, Astor BC, Mandelbrot D, Hidalgo L, Djamali A.
    Clin Nephrol; 2020 Nov 15; 94(5):245-251. PubMed ID: 32870149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.